ArticleStem cells translational medicine2025
Microencapsulated 3D culture of human umbilical cord-derived mesenchymal stem cells enhances their therapeutic effect on intrauterine adhesion.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endometrial Repair and Regenerative Medicine: From Broad-Spectrum Regeneration to Precision Intervention.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Therapeutic application of mesenchymal stem cells is emerging as a potential strategy for the management of intrauterine adhesion (IUA). However, conventional 2D cultures often face issues such as insufficient cell quantities and suboptimal efficacy. In this study, we investigated the potential of microencapsulated 3D culture in enhancing the proliferation and stemness of human umbilical cord-derived mesenchymal stem cells (hUCMSCs), and their potential augmentation for antifibrotic treatment of IUA via the transforming growth factor beta 1 (TGF-β1)/Smad3 signaling pathway. Here, hUCMSCs were encapsulated in sodium alginate shells, and the microencapsulated 3D culture of hUCMSCs (3D-hUCMSCs) was harvested after removal of the encapsulation. We assessed the amount, cell proliferation, and the stemness gene expression of 3D-hUCMSCs and 2D cultured hUCMSCs. Subsequently, the therapeutic effect of 3D-hUCMSCs was evaluated by specific staining and mating experiments in the IUA mouse model. The expression of the TGF-β1/Smad3 signaling pathway was analyzed by western blot and quantitative real-time polymerase chain reaction. Our results showed that microencapsulated 3D culture significantly enhanced cell proliferation and elevated stemness gene expression, compared to traditional 2D culture. Furthermore, the endometrial thickness and number of glands increased, and the endometrial fibrosis and inflammation ameliorated in 3D-hUCMSCs administration. Moreover, 3D-hUCMSCs significantly inhibited the expression of the TGF-β1/Smad3 signaling pathway and restored the fertility. These findings indicate that microencapsulated 3D culture enhances cell proliferation and stemness of hUCMSCs. The 3D-hUCMSCs improved the endometrial recovery in structure and function. Microencapsulated 3D culture promoted the antifibrotic and anti-inflammatory effects of hUCMSCs in the treatment of IUA. This study introduces a novel strategy of microencapsulated 3D-hUCMSCs for IUA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.